Chiusura precedente | 1,2900 |
Aperto | 1,2700 |
Denaro | 1,2300 x 900 |
Lettera | 1,3200 x 1100 |
Min-Max giorno | 1,2300 - 1,3200 |
Intervallo di 52 settimane | 1,2300 - 14,4900 |
Volume | |
Media Volume | 1.327.983 |
Capitalizzazione | 81,157M |
Beta (5 anni mensile) | 0,49 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,4500 |
Prossima data utili | 30 mar 2023 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 6,50 |
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2022 before the market opens on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the “Settlement Agreement”) with the former CartiHeal shareholders (the “CartiHeal Sellers”) regarding the Company’s obligations under the amended Option and Equity Purchase Agreement for its prior acquisition of CartiHeal (the “Amended Acquisition Agreement”). The Settlemen
DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 10, 2023. About BioventusBio